Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genprex, Inc. (NASDAQ: GNPX) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a clinical-stage gene therapy company, Genprex uses these filings to describe its oncology and diabetes pipelines, financing activities, and Nasdaq listing status.
Key documents include registration statements such as Form S-1 and Form S-3, where Genprex outlines its business overview, risk factors, and details of equity offerings and warrant structures. These filings describe the company’s focus on Reqorsa Gene Therapy (quaratusugene ozeplasmid) for non-small cell and small cell lung cancer, the Oncoprex Delivery System, and the GPX-002 diabetes gene therapy program using AAV delivery of Pdx1 and MafA genes to the pancreas.
Investors can also review Form 8-K current reports that document material events. Recent 8-Ks discuss registered direct offerings and concurrent private placements, at-the-market program updates, new patents and patent intentions around Reqorsa combinations with PD-1 and PD-L1 antibodies, additions of clinical trial sites for Acclaim-1 and Acclaim-3, and communications with Nasdaq regarding minimum bid price and stockholders’ equity requirements.
On Stock Titan, AI-powered tools summarize lengthy prospectuses and current reports, helping readers quickly identify sections related to gene therapy mechanisms, clinical trial design, regulatory designations, and capital-raising terms. As new filings appear on EDGAR, they are reflected here in near real time, giving users an organized view of Genprex’s regulatory history, financing transactions, and disclosures relevant to GNPX stock.
Genprex announced positive preclinical data for GPX-002, its diabetes gene therapy candidate, presented at the 2025 ADA Scientific Sessions. The research showcased a novel non-viral delivery approach using lipid nanoparticles (LNPs), marking a significant advancement in diabetes treatment technology.
Key findings include:
- Successful testing of 9 LNPs with patented LipexSil® lipids, demonstrating efficient cell transfection in mouse Islets of Langerhans
- ALX-184 LNP showed particular promise in crossing the pancreatic membrane and effectively delivering mRNA payloads
- The non-viral delivery system potentially enables repeat dosing without immunosuppression, a significant advantage over traditional AAV delivery methods
This research runs parallel to Genprex's ongoing AAV construct studies, representing a strategic expansion of their diabetes program. The company believes these findings provide crucial proof of concept for advancing their Type 1 diabetes treatment approach, though they caution that all forward-looking statements are subject to risks and uncertainties.